{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T18:22:34Z","timestamp":1770834154193,"version":"3.50.1"},"reference-count":113,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Jilin Province Health Science and Technology Capacity Improvement Project","award":["2024A088"],"award-info":[{"award-number":["2024A088"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitors (ICIs), such as PD-1, PD-L1, and CTLA-4 inhibitors, enhance immune function by targeting T-cell surface receptors, overcoming natural immune inhibition. These drugs activate the immune system to detect and target cancer cells, providing an alternative therapeutic approach, particularly in cases where conventional treatments fail. However, the growing use of ICIs has highlighted several defence-related adverse events, particularly cardiac toxicity, including acute myocarditis, atherosclerosis, and heart failure unrelated to myocarditis. These complications present significant challenges, limiting the broader use of ICIs. Research into the cardiac toxicity of ICIs is still in its early stages, and the underlying mechanisms remain unclear. This review consolidates current findings on ICI-associated heart damage, explores potential factors contributing to ICI-induced cardiac injury, and evaluates preventive and therapeutic strategies. This work aims to provide a theoretical foundation for medical intervention and prevention of ICI-related cardiac damage.<\/jats:p>","DOI":"10.1093\/eschf\/xvaf015","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T18:29:41Z","timestamp":1768328981000},"source":"Crossref","is-referenced-by-count":0,"title":["Immune checkpoint inhibition and heart injury: molecular mechanisms and clinical challenges"],"prefix":"10.1093","volume":"13","author":[{"given":"Shan","family":"Lv","sequence":"first","affiliation":[{"name":"Department of Cardiology, The Affiliated Hospital to Changchun University of Chinese Medicine , Changchun 130021 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianan","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Oncology, The Affiliated Hospital to Changchun University of Chinese Medicine , Changchun 130021 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liyue","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Changchun Hospital of Traditional Chinese Medicine , Changchun 130051 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junfeng","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Affiliated Hospital to Changchun University of Chinese Medicine , Changchun 130021 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuning","family":"Xin","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Affiliated Hospital to Changchun University of Chinese Medicine , Changchun 130021 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Oncology, The Affiliated Hospital to Changchun University of Chinese Medicine , Changchun 130021 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengfei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Affiliated Hospital to Changchun University of Chinese Medicine , Changchun 130021 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huize","family":"Han","sequence":"additional","affiliation":[{"name":"College of Traditional Chinese Medicine, Changchun University of Chinese Medicine , Changchun 130117 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[{"name":"College of Traditional Chinese Medicine, Changchun University of Chinese Medicine , Changchun 130117 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aidong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Third Affiliated Clinical Hospital to Changchun University of Chinese Medicine , No. 1643, Jingyue Street, Changchun, Jilin Province 130022 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"2026021112471133500_xvaf015-B1","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"key":"2026021112471133500_xvaf015-B2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41571-021-00564-3","article-title":"Tumour burden and efficacy of immune-checkpoint inhibitors","volume":"19","author":"Dall'olio","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"2026021112471133500_xvaf015-B3","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.trecan.2023.04.002","article-title":"Immune mechanisms of toxicity from checkpoint inhibitors","volume":"9","author":"Wang","year":"2023","journal-title":"Trends Cancer"},{"key":"2026021112471133500_xvaf015-B4","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12964-022-00854-y","article-title":"Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons","volume":"20","author":"Naimi","year":"2022","journal-title":"Cell Commun Signal"},{"key":"2026021112471133500_xvaf015-B5","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.semcancer.2022.12.003","article-title":"Synergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines","volume":"88","author":"Oladejo","year":"2023","journal-title":"Semin Cancer Biol"},{"key":"2026021112471133500_xvaf015-B6","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/hep.32340","article-title":"Combining immune checkpoint inhibitors with immunomodulators: lessons from different metastatic sites","volume":"76","author":"Cinnamon","year":"2022","journal-title":"Hepatology"},{"key":"2026021112471133500_xvaf015-B7","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12943-024-02179-5","article-title":"Current trends in sensitizing immune checkpoint inhibitors for cancer treatment","volume":"23","author":"Wei","year":"2024","journal-title":"Mol Cancer"},{"key":"2026021112471133500_xvaf015-B8","doi-asserted-by":"publisher","first-page":"102614","DOI":"10.1016\/j.ctrv.2023.102614","article-title":"Novel targets for immune-checkpoint inhibition in cancer","volume":"120","author":"Borgeaud","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"2026021112471133500_xvaf015-B9","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.annonc.2024.06.008","article-title":"Immune checkpoint inhibitors in endometrial cancer: a cinderella story","volume":"35","author":"Colombo","year":"2024","journal-title":"Ann Oncol"},{"key":"2026021112471133500_xvaf015-B10","doi-asserted-by":"publisher","first-page":"216038","DOI":"10.1016\/j.canlet.2022.216038","article-title":"Immune checkpoint inhibitor resistance in hepatocellular carcinoma","volume":"555","author":"Wang","year":"2023","journal-title":"Cancer Lett"},{"key":"2026021112471133500_xvaf015-B11","doi-asserted-by":"publisher","first-page":"633","DOI":"10.20892\/j.issn.2095-3941.2023.0201","article-title":"Biomarkers for immune checkpoint inhibitors in colorectal cancer: recent advances and future perspectives","volume":"20","author":"Yang","year":"2023","journal-title":"Cancer Biol Med"},{"key":"2026021112471133500_xvaf015-B12","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.tips.2024.04.006","article-title":"Immune checkpoint blockade resistance in lung cancer: emerging mechanisms and therapeutic opportunities","volume":"45","author":"Konen","year":"2024","journal-title":"Trends Pharmacol Sci"},{"key":"2026021112471133500_xvaf015-B13","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0140-6736(23)00922-4","article-title":"Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial","volume":"402","author":"Pal","year":"2023","journal-title":"Lancet"},{"key":"2026021112471133500_xvaf015-B14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ctrv.2017.12.007","article-title":"Immune checkpoint inhibitors for metastatic bladder cancer","volume":"64","author":"Massari","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"2026021112471133500_xvaf015-B15","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2026021112471133500_xvaf015-B16","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.jaad.2020.09.054","article-title":"Cutaneous adverse events caused by immune checkpoint inhibitors","volume":"85","author":"Quach","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2026021112471133500_xvaf015-B17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/imr.13239","article-title":"Gastrointestinal mucosal toxicities from immune checkpoint inhibitors: current understanding and future directions","volume":"318","author":"Dougan","year":"2023","journal-title":"Immunol Rev"},{"key":"2026021112471133500_xvaf015-B18","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1159\/000518543","article-title":"Gastrointestinal adverse events induced by immune-checkpoint inhibitors","volume":"102","author":"Yanai","year":"2021","journal-title":"Digestion"},{"key":"2026021112471133500_xvaf015-B19","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"2026021112471133500_xvaf015-B20","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1159\/000509941","article-title":"Immune checkpoint inhibitor-related pneumonitis","volume":"99","author":"Gomatou","year":"2020","journal-title":"Respiration"},{"key":"2026021112471133500_xvaf015-B21","doi-asserted-by":"publisher","first-page":"1115305","DOI":"10.3389\/fimmu.2023.1115305","article-title":"Immune checkpoint inhibitors related respiratory disorders in patients with lung cancer: a meta-analysis of randomized controlled trials","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"},{"key":"2026021112471133500_xvaf015-B22","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.gastrohep.2023.10.009","article-title":"Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: position statement of the AEEH-AEG-SEPD-SEOM-GETECCU","volume":"47","author":"Riveiro-Barciela","year":"2024","journal-title":"Gastroenterol Hepatol"},{"key":"2026021112471133500_xvaf015-B23","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S1474-4422(23)00369-1","article-title":"Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes","volume":"23","author":"Farina","year":"2024","journal-title":"Lancet Neurol"},{"key":"2026021112471133500_xvaf015-B24","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/S1474-4422(23)00335-6","article-title":"Neurological adverse events related to immune-checkpoint inhibitors in Spain: a retrospective cohort study","volume":"22","author":"Fonseca","year":"2023","journal-title":"Lancet Neurol"},{"key":"2026021112471133500_xvaf015-B25","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/s41581-022-00630-8","article-title":"Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury","volume":"18","author":"Sprangers","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"2026021112471133500_xvaf015-B26","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/cac2.12396","article-title":"Comparative risk of acute kidney injury among cancer patients treated with immune checkpoint inhibitors","volume":"43","author":"Liu","year":"2023","journal-title":"Cancer Commun (Lond)"},{"key":"2026021112471133500_xvaf015-B27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41467-021-27631-8","article-title":"Systematic analysis of drug-associated myocarditis reported in the World Health Organization pharmacovigilance database","volume":"13","author":"Nguyen","year":"2022","journal-title":"Nat Commun"},{"key":"2026021112471133500_xvaf015-B28","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1002\/ehf2.15363","article-title":"Early diagnostic value of novel biomarkers for breast cancer therapy-related cardiac dysfunction","volume":"19","author":"Wang","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026021112471133500_xvaf015-B29","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.jacc.2023.12.024","article-title":"2024 ACC expert consensus decision pathway for treatment of heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"83","author":"Maddox","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026021112471133500_xvaf015-B30","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s40264-023-01320-5","article-title":"Cardiovascular toxicity of immune checkpoint inhibitors: a guide for clinicians","volume":"46","author":"Raschi","year":"2023","journal-title":"Drug Saf"},{"key":"2026021112471133500_xvaf015-B31","doi-asserted-by":"publisher","first-page":"102283","DOI":"10.1016\/j.coi.2023.102283","article-title":"Immune checkpoint receptors in autoimmunity","volume":"80","author":"Burke","year":"2023","journal-title":"Curr Opin Immunol"},{"key":"2026021112471133500_xvaf015-B32","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41590-021-01125-7","article-title":"PD-1 agonism by anti-CD80 inhibits T cell activation and alleviates autoimmunity","volume":"23","author":"Sugiura","year":"2022","journal-title":"Nat Immunol"},{"key":"2026021112471133500_xvaf015-B33","doi-asserted-by":"publisher","first-page":"216726","DOI":"10.1016\/j.canlet.2024.216726","article-title":"PD-1 regulation in immune homeostasis and immunotherapy","volume":"588","author":"Gao","year":"2024","journal-title":"Cancer Lett"},{"key":"2026021112471133500_xvaf015-B34","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","article-title":"CTLA-4: a moving target in immunotherapy","volume":"131","author":"Rowshanravan","year":"2018","journal-title":"Blood"},{"key":"2026021112471133500_xvaf015-B35","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.semcancer.2021.05.022","article-title":"The depths of PD-1 function within the tumor microenvironment beyond CD8(+) T cells","volume":"86","author":"Laba","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"2026021112471133500_xvaf015-B36","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.it.2006.02.001","article-title":"The PD-1-PD-L pathway in immunological tolerance","volume":"27","author":"Okazaki","year":"2006","journal-title":"Trends Immunol"},{"key":"2026021112471133500_xvaf015-B37","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jconrel.2022.07.010","article-title":"Antibody-mediated depletion of programmed death 1-positive (PD-1(+)) cells","volume":"349","author":"Zhai","year":"2022","journal-title":"J Control Release"},{"key":"2026021112471133500_xvaf015-B38","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s13046-021-01987-7","article-title":"Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer","volume":"40","author":"Zhang","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"2026021112471133500_xvaf015-B39","doi-asserted-by":"publisher","first-page":"1198365","DOI":"10.3389\/fimmu.2023.1198365","article-title":"Current understanding of CTLA-4: from mechanism to autoimmune diseases","volume":"14","author":"Hossen","year":"2023","journal-title":"Front Immunol"},{"key":"2026021112471133500_xvaf015-B40","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science (New York, NY)"},{"key":"2026021112471133500_xvaf015-B41","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"key":"2026021112471133500_xvaf015-B42","doi-asserted-by":"publisher","first-page":"9958","DOI":"10.3390\/ijms23179958","article-title":"LAG-3 as a potent target for novel anticancer therapies of a wide range of tumors","volume":"23","author":"Sauer","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026021112471133500_xvaf015-B43","doi-asserted-by":"publisher","first-page":"eadf2223","DOI":"10.1126\/sciimmunol.adf2223","article-title":"Beyond T cell exhaustion: TIM-3 regulation of myeloid cells","volume":"9","author":"Dixon","year":"2024","journal-title":"Sci Immunol"},{"key":"2026021112471133500_xvaf015-B44","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","article-title":"Tumor-infiltrating lymphocyte therapy or Ipilimumab in advanced melanoma","volume":"387","author":"Rohaan","year":"2022","journal-title":"N Engl J Med"},{"key":"2026021112471133500_xvaf015-B45","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMoa2212851","article-title":"Cabozantinib plus nivolumab and ipilimumab in renal-cell carcinoma","volume":"388","author":"Choueiri","year":"2023","journal-title":"N Engl J Med"},{"key":"2026021112471133500_xvaf015-B46","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/s41586-022-04508-4","article-title":"Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer","volume":"603","author":"Shitara","year":"2022","journal-title":"Nature"},{"key":"2026021112471133500_xvaf015-B47","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1056\/NEJMoa2215530","article-title":"Perioperative nivolumab and chemotherapy in stage III non-small-cell lung cancer","volume":"389","author":"Provencio","year":"2023","journal-title":"N Engl J Med"},{"key":"2026021112471133500_xvaf015-B48","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1182\/blood.2019003886","article-title":"Nivolumab treatment of relapsed\/refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults","volume":"135","author":"Liu","year":"2020","journal-title":"Blood"},{"key":"2026021112471133500_xvaf015-B49","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.oraloncology.2018.04.008","article-title":"Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression","volume":"81","author":"Ferris","year":"2018","journal-title":"Oral Oncol"},{"key":"2026021112471133500_xvaf015-B50","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"2026021112471133500_xvaf015-B51","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1080\/21645515.2016.1199310","article-title":"Pembrolizumab (Keytruda)","volume":"12","author":"Kwok","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"2026021112471133500_xvaf015-B52","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 Blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N Engl J Med"},{"key":"2026021112471133500_xvaf015-B53","volume-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury","author":"Cemiplimab","year":"2012"},{"key":"2026021112471133500_xvaf015-B54","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1007\/s40265-020-01398-6","article-title":"Atezolizumab: a review in extensive-stage SCLC","volume":"80","author":"Frampton","year":"2020","journal-title":"Drugs"},{"key":"2026021112471133500_xvaf015-B55","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"2026021112471133500_xvaf015-B56","volume-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury","author":"Avelumab","year":"2012"},{"key":"2026021112471133500_xvaf015-B57","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s11523-021-00843-0","article-title":"Durvalumab: a review in extensive-stage SCLC","volume":"16","author":"Al-Salama","year":"2021","journal-title":"Target Oncol"},{"key":"2026021112471133500_xvaf015-B58","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.jtho.2020.12.015","article-title":"Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC-an update from the PACIFIC trial","volume":"16","author":"Faivre-Finn","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2026021112471133500_xvaf015-B59","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.annonc.2022.12.008","article-title":"Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study","volume":"34","author":"Psyrri","year":"2023","journal-title":"Ann Oncol"},{"key":"2026021112471133500_xvaf015-B60","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.2217\/fon-2021-1647","article-title":"KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer","volume":"18","author":"Rizzo","year":"2022","journal-title":"Future Oncol"},{"key":"2026021112471133500_xvaf015-B61","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s12029-023-00927-2","article-title":"Immune checkpoint inhibitors in pMMR\/MSS colorectal cancer","volume":"54","author":"El Hajj","year":"2023","journal-title":"J Gastrointest Cancer"},{"key":"2026021112471133500_xvaf015-B62","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1080\/13543784.2021.1940948","article-title":"Potential experimental immune checkpoint inhibitors for the treatment of cancer of the liver","volume":"30","author":"Hewitt","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"2026021112471133500_xvaf015-B63","doi-asserted-by":"publisher","first-page":"103666","DOI":"10.1016\/j.drudis.2023.103666","article-title":"PD-1\/PD-L1 immune checkpoint blockade in ovarian cancer: dilemmas and opportunities","volume":"28","author":"Peng","year":"2023","journal-title":"Drug Discov Today"},{"key":"2026021112471133500_xvaf015-B64","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1038\/s41416-021-01425-7","article-title":"Resistance to immune checkpoint inhibitors in advanced gastro-oesophageal cancers","volume":"125","author":"Baxter","year":"2021","journal-title":"Br J Cancer"},{"key":"2026021112471133500_xvaf015-B65","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"2026021112471133500_xvaf015-B66","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026021112471133500_xvaf015-B67","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"2026021112471133500_xvaf015-B68","doi-asserted-by":"publisher","first-page":"4964","DOI":"10.1093\/eurheartj\/ehab618","article-title":"Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis","volume":"42","author":"Dolladille","year":"2021","journal-title":"Eur Heart J"},{"key":"2026021112471133500_xvaf015-B69","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1001\/jamaoncol.2019.3113","article-title":"Factors associated with immune checkpoint inhibitor-related myocarditis","volume":"5","author":"Zamami","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026021112471133500_xvaf015-B70","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1002\/ejhf.806","article-title":"Immune-related fulminant myocarditis in a patient receiving ipilimumab therapy for relapsed chronic myelomonocytic leukaemia","volume":"19","author":"Berg","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026021112471133500_xvaf015-B71","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1002\/ejhf.2289","article-title":"Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis","volume":"23","author":"Rubio-Infante","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026021112471133500_xvaf015-B72","doi-asserted-by":"publisher","first-page":"e000247","DOI":"10.1136\/esmoopen-2017-000247","article-title":"Cardiotoxicity of immune checkpoint inhibitors","volume":"2","author":"Varricchi","year":"2017","journal-title":"ESMO Open"},{"key":"2026021112471133500_xvaf015-B73","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1038\/s41401-018-0062-2","article-title":"Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity","volume":"39","author":"Zhang","year":"2018","journal-title":"Acta Pharmacol Sin"},{"key":"2026021112471133500_xvaf015-B74","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","article-title":"Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"2026021112471133500_xvaf015-B75","doi-asserted-by":"publisher","first-page":"4458","DOI":"10.1093\/eurheartj\/ehac456","article-title":"Cardiovascular complications of immune checkpoint inhibitors for cancer","volume":"43","author":"Thuny","year":"2022","journal-title":"Eur Heart J"},{"key":"2026021112471133500_xvaf015-B76","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/onco.13931","article-title":"Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases","volume":"26","author":"Pathak","year":"2021","journal-title":"Oncologist"},{"key":"2026021112471133500_xvaf015-B77","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.3390\/diagnostics14161794","article-title":"Myocarditis, myositis, and myasthenia gravis overlap syndrome associated with immune checkpoint inhibitors: a systematic review","volume":"14","author":"Lipe","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"2026021112471133500_xvaf015-B78","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity","volume":"19","author":"Lyon","year":"2018","journal-title":"Lancet Oncol"},{"key":"2026021112471133500_xvaf015-B79","doi-asserted-by":"publisher","first-page":"779691","DOI":"10.3389\/fimmu.2022.779691","article-title":"Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors","volume":"13","author":"Chennamadhavuni","year":"2022","journal-title":"Front Immunol"},{"key":"2026021112471133500_xvaf015-B80","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1002\/ejhf.3340","article-title":"Cardiovascular toxicities of immune therapies for cancer\u2014a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology","volume":"26","author":"Tocchetti","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026021112471133500_xvaf015-B81","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1001\/jamacardio.2021.2241","article-title":"Clinical strategy for the diagnosis and treatment of immune checkpoint inhibitor-associated myocarditis: a narrative review","volume":"6","author":"Lehmann","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2026021112471133500_xvaf015-B82","doi-asserted-by":"publisher","first-page":"726426","DOI":"10.3389\/fcvm.2021.726426","article-title":"Immune checkpoint inhibitors and the heart","volume":"8","author":"Mocan-Hognogi","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"2026021112471133500_xvaf015-B83","doi-asserted-by":"publisher","first-page":"922782","DOI":"10.3389\/fimmu.2022.922782","article-title":"TNF-\u03b1 inhibitors and other biologic agents for the treatment of immune checkpoint inhibitor-induced myocarditis","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"2026021112471133500_xvaf015-B84","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3389\/fmed.2022.875974","article-title":"Adverse events of immune checkpoint inhibitors and their treatment","volume":"63","author":"Dienes","year":"2019","journal-title":"Magy Onkol"},{"key":"2026021112471133500_xvaf015-B85","doi-asserted-by":"publisher","first-page":"eabo1981","DOI":"10.1126\/scitranslmed.abo1981","article-title":"Hormonal therapies up-regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis","volume":"14","author":"Zhang","year":"2022","journal-title":"Sci Transl Med"},{"key":"2026021112471133500_xvaf015-B86","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1007\/s11427-022-2273-3","article-title":"Immunopathogenesis and immunomodulatory therapy for myocarditis","volume":"66","author":"He","year":"2023","journal-title":"Sci China Life Sci"},{"key":"2026021112471133500_xvaf015-B87","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1161\/CIRCULATIONAHA.121.056730","article-title":"Identification of pathogenic immune cell subsets associated with checkpoint inhibitor-induced myocarditis","volume":"146","author":"Zhu","year":"2022","journal-title":"Circulation"},{"key":"2026021112471133500_xvaf015-B88","doi-asserted-by":"publisher","first-page":"H751","DOI":"10.1152\/ajpheart.00378.2023","article-title":"Immune interactions in pembrolizumab (PD-1 inhibitor) cancer therapy and cardiovascular complications","volume":"325","author":"Banerjee","year":"2023","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026021112471133500_xvaf015-B89","doi-asserted-by":"publisher","first-page":"e2323052121","DOI":"10.1073\/pnas.2323052121","article-title":"Injury-induced myosin-specific tissue-resident memory T cells drive immune checkpoint inhibitor myocarditis","volume":"121","author":"Kalinoski","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026021112471133500_xvaf015-B90","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.3390\/ijms21072399","article-title":"Programmed cell death-1: programmed cell death-ligand 1 interaction protects human cardiomyocytes against T-cell mediated inflammation and apoptosis response in vitro","volume":"21","author":"Tay","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026021112471133500_xvaf015-B91","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41586-022-05432-3","article-title":"T cells specific for \u03b1-myosin drive immunotherapy-related myocarditis","volume":"611","author":"Axelrod","year":"2022","journal-title":"Nature"},{"key":"2026021112471133500_xvaf015-B92","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.122.062551","article-title":"Expansion of pathogenic cardiac macrophages in immune checkpoint inhibitor myocarditis","volume":"149","author":"Ma","year":"2024","journal-title":"Circulation"},{"key":"2026021112471133500_xvaf015-B93","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1161\/CIRCRESAHA.124.325652","article-title":"Novel therapeutic approach targeting CXCR3 to treat immunotherapy myocarditis","volume":"136","author":"Huang","year":"2025","journal-title":"Circ Res"},{"key":"2026021112471133500_xvaf015-B94","doi-asserted-by":"publisher","first-page":"156873","DOI":"10.1016\/j.cyto.2025.156873","article-title":"Immune checkpoint inhibitors mediate myocarditis by promoting macrophage polarization via cGAS\/STING pathway","volume":"187","author":"Cao","year":"2025","journal-title":"Cytokine"},{"key":"2026021112471133500_xvaf015-B95","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s00011-024-01979-1","article-title":"Mediation of macrophage M1 polarization dynamics change by ubiquitin-autophagy-pathway regulated NLRP3 inflammasomes in PD-1 inhibitor-related myocardial inflammatory injury","volume":"74","author":"Chen","year":"2025","journal-title":"Inflamm Res"},{"key":"2026021112471133500_xvaf015-B96","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s41419-020-02778-2","article-title":"Immune checkpoint inhibitor induces cardiac injury through polarizing macrophages via modulating microRNA-34a\/Kruppel-like factor 4 signaling","volume":"11","author":"Xia","year":"2020","journal-title":"Cell Death Dis"},{"key":"2026021112471133500_xvaf015-B97","doi-asserted-by":"publisher","first-page":"e001293","DOI":"10.1136\/jitc-2020-001293","article-title":"PD-1 inhibitor inducing exosomal miR-34a-5p expression mediates the cross talk between cardiomyocyte and macrophage in immune checkpoint inhibitor-related cardiac dysfunction","volume":"8","author":"Xia","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026021112471133500_xvaf015-B98","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/s42003-023-05338-4","article-title":"ANGPTL2 promotes immune checkpoint inhibitor-related murine autoimmune myocarditis","volume":"6","author":"Horiguchi","year":"2023","journal-title":"Commun Biol"},{"key":"2026021112471133500_xvaf015-B99","doi-asserted-by":"publisher","first-page":"e2400486","DOI":"10.1002\/advs.202400486","article-title":"Anti-CTLA-4 m2a antibody exacerbates cardiac injury in experimental autoimmune myocarditis mice by promoting Ccl5-neutrophil infiltration","volume":"11","author":"Wu","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"2026021112471133500_xvaf015-B100","doi-asserted-by":"publisher","first-page":"1549487","DOI":"10.3389\/fphar.2025.1549487","article-title":"PD-1 inhibition disrupts collagen homeostasis and aggravates cardiac dysfunction through endothelial-fibroblast crosstalk and EndMT","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Pharmacol"},{"key":"2026021112471133500_xvaf015-B101","doi-asserted-by":"publisher","first-page":"6640","DOI":"10.1038\/s41467-024-50996-5","article-title":"Gasdermin-E-mediated pyroptosis drives immune checkpoint inhibitor-associated myocarditis via cGAS-STING activation","volume":"15","author":"Sun","year":"2024","journal-title":"Nat Commun"},{"key":"2026021112471133500_xvaf015-B102","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s10753-024-02056-9","article-title":"PD-1 inhibitor aggravate irradiation-induced myocardial fibrosis by regulating TGF-\u03b21\/Smads signaling pathway via GSDMD-mediated pyroptosis","volume":"48","author":"Wu","year":"2025","journal-title":"Inflammation"},{"key":"2026021112471133500_xvaf015-B103","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1093\/eurheartj\/ehab430","article-title":"Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy","volume":"43","author":"Michel","year":"2022","journal-title":"Eur Heart J"},{"key":"2026021112471133500_xvaf015-B104","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1111\/bph.15984","article-title":"Characterization of immune checkpoint inhibitor-induced cardiotoxicity reveals interleukin-17A as a driver of cardiac dysfunction after anti-PD-1 treatment","volume":"180","author":"Gergely","year":"2023","journal-title":"Br J Pharmacol"},{"key":"2026021112471133500_xvaf015-B105","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/s43018-024-00810-4","article-title":"A targetable type III immune response with increase of IL-17A expressing CD4(+) T cells is associated with immunotherapy-induced toxicity in melanoma","volume":"5","author":"Dimitriou","year":"2024","journal-title":"Nat Cancer"},{"key":"2026021112471133500_xvaf015-B106","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-025-02298-1","article-title":"MLKL-mediated necroptosis predominantly contributes to immune-associated myocardial damage","author":"Sun","year":"2025","journal-title":"Inflammation"},{"key":"2026021112471133500_xvaf015-B107","doi-asserted-by":"publisher","first-page":"5529","DOI":"10.1038\/s41467-023-41066-3","article-title":"Fasting mimicking diet in mice delays cancer growth and reduces immunotherapy-associated cardiovascular and systemic side effects","volume":"14","author":"Cortellino","year":"2023","journal-title":"Nat Commun"},{"key":"2026021112471133500_xvaf015-B108","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1038\/s41467-025-58107-8","article-title":"Microbiota-indole-3-propionic acid-heart axis mediates the protection of leflunomide against \u03b1PD1-induced cardiotoxicity in mice","volume":"16","author":"Huang","year":"2025","journal-title":"Nat Commun"},{"key":"2026021112471133500_xvaf015-B109","doi-asserted-by":"publisher","first-page":"114676","DOI":"10.1016\/j.intimp.2025.114676","article-title":"L-Kynurenine regulates immune response in ICIs-associated myocarditis via JAK\/STAT pathway","volume":"156","author":"He","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"2026021112471133500_xvaf015-B110","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.2147\/JIR.S348464","article-title":"Protective effect of crocin on immune checkpoint inhibitors-related myocarditis through inhibiting NLRP3 mediated pyroptosis in cardiomyocytes via NF-\u03baB pathway","volume":"15","author":"Zhang","year":"2022","journal-title":"J Inflamm Res"},{"key":"2026021112471133500_xvaf015-B111","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1146\/annurev-biochem-013118-111902","article-title":"Exosomes","volume":"88","author":"Pegtel","year":"2019","journal-title":"Annu Rev Biochem"},{"key":"2026021112471133500_xvaf015-B112","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ymthe.2020.11.030","article-title":"Plant exosome-like nanovesicles: emerging therapeutics and drug delivery nanoplatforms","volume":"29","author":"Dad","year":"2021","journal-title":"Mol Ther"},{"key":"2026021112471133500_xvaf015-B113","doi-asserted-by":"publisher","first-page":"123108","DOI":"10.1016\/j.lfs.2024.123108","article-title":"Exosomes from human bone marrow MSCs alleviate PD-1\/PD-L1 inhibitor-induced myocardial injury in melanoma mice by regulating macrophage polarization and pyroptosis","volume":"358","author":"Zhou","year":"2024","journal-title":"Life Sci"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/advance-article-pdf\/doi\/10.1093\/eschf\/xvaf015\/66398773\/xvaf015.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/13\/1\/xvaf015\/66398773\/xvaf015.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/13\/1\/xvaf015\/66398773\/xvaf015.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T17:47:17Z","timestamp":1770832037000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/doi\/10.1093\/eschf\/xvaf015\/8424682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":113,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,13]]},"published-print":{"date-parts":[[2026,2,3]]}},"URL":"https:\/\/doi.org\/10.1093\/eschf\/xvaf015","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,13]]},"article-number":"xvaf015"}}